Instruction for use: EglonilI want this, give me price
Packing: tablets, capsules
Active substance: Sulpiride
Composition and release form
Capsules 1 caps.
Sulpiride 50 mg
in a blister of 10 pcs .; in the box 3 blisters.
Tablets 1 table.
Sulpiride 200 mg
12 pieces in the blister; in the box 1 blister.
Solution for intramuscular injection 1 amp.
Sulpiride 100 mg
6 ampoules in the blister; in the box 1 blister.
Solution for oral administration (preferably for children) 0.5% 100 ml
Sulpiride 500 mg
(1 tsp lodka 5 ml - 25 mg and 20 drops - 5 mg)
in glass bottles of 200 ml.
Pharmacological action - antipsychotic.
Blocks dopamine receptors.
In small doses, acting at the level of the central dopaminergic receptors, exerts a disinhibiting effect. In doses over 600 mg / day reduces the productive symptoms (actually the antipsychotic effect).
After parenteral administration, 100 mg of Cmax (2.2 mg / L) is determined after 30 minutes, after oral administration of 200 mg (0.73 mg / l) after 4.5 hours. Bioavailability after oral administration is 25-35% (may vary considerably among the individual patients). Easily penetrates into all organs, especially rapidly in the liver and kidneys, more slowly in the brain tissue (the main amount is concentrated in the pituitary gland). Binding to plasma proteins - 40%. T1 / 2 is about 7 hours. Practically not exposed to biotransformation. Total Cl: 126 ml / min. Excretion is mainly carried out by the kidneys (92% of the administered dose) by glomerular filtration and secretion; A small part (about 1% of the daily dose) is excreted in breast milk.
Indications of the preparation Eglonil
Acute and chronic psychoses (retardation, delirium, confusion, agrammatism, abulia), schizophrenia; neurotic states, accompanied by retardation; psychosomatic symptoms (especially with peptic ulcer of the stomach and duodenum and hemorrhagic rectocolitis).
Hypersensitivity, suspicion of pheochromocytoma.
Application in pregnancy and lactation
With prolonged use of high doses (over 200 mg / day), newborns sometimes had an extrapyramidal syndrome. Therefore, when it is necessary to carry out treatment in pregnant and lactating women, it is recommended to lower the dose and reduce the duration of treatment.
With prolonged use in high doses, sometimes inhibition, drowsiness, hyperprolactinaemia, amenorrhea, galactorrhea, gynecomastia, impotence, frigidity, weight gain, early (spastic, torticollis, oculomotor disorders, spasm of the masticatory musculature) and late dyskinesias, extrapyramidal disorders, orthostatic hypotension , malignant neuroleptic syndrome (hyperthermia).
Weakens the effect of levodopa, increases the severity of lowering blood pressure on the background of antihypertensive drugs; is incompatible with alcohol and other drugs that depress the central nervous system (mutual enhancement of sedative properties).
Dosing and Administration
Psychoses: IM - 200-800 mg / day for 2 weeks; inside - with negative symptoms - 200-600 mg / day, with productive symptoms - at 800-1600 mg / day, with motor retardation and psychosomatic disorders - 100-200 mg / day, with peptic ulcer of the stomach and duodenum - 150 mg / day for 4-6 weeks. Children (preferably in the form of a solution for oral administration) - 5-10 mg / kg / day (1 tea - 25 mg, 4 drops - 1 mg).
Be wary appoint patients with kidney failure, epilepsy, Parkinsonism, the elderly and the newborn; during work drivers of vehicles and people whose profession is associated with increased concentration of attention.
Storage conditions for Eglonil
At a temperature not exceeding 30 ° C.
Keep out of the reach of children.
Shelf life of Eglonil
Do not use after the expiry date printed on the package.